Check this!Transradial approach for carotid artery stenting - A position paper from the Italian Society of Interventional Cardiology (SICI‐GISE)
Check my new article about Paclitaxel-Eluting Stent written through collaboration with dr. Farhat Fouladvant.Is Paclitaxel-Eluting Stent Use Justified by an Adequate Risk Profile
EASTBOURNE registry finished the enrollment a few days ago, with the terrific number of 2100 patients reached: this is the largest coronary DCB study ever done.
EASTBOURNE is a prospective registry and will describe the immediate and long term performance of the novel Magic Touch sirolimus-coated balloon for any coronary application. Interesting, this is an investigator-driven study without bias or inferences from the industry.
I want to congratulate each investigator of the study and Prof Antonio Colombo, co-chairman of the study.
Top enrollers are: L. Testa, T. Heang, A. Ielasi, I. Bossi, R. Latini, L. Yan, I. Sanchez, D. Milazzo, G. Caiazzo, F. Tomai, G. Di Palma, S. Benincasa, M. Montorfano, A. Nuruddin, G. Stefanini, G. Seresini, R. Singh, G. Cacucci.
You can find the interim analysis publication (600 pts @1y.) here: https://pubmed.ncbi.nlm.nih.gov/32740442/
Bernardo Cortese, MD FESC
It is my privilege to announce that PICCOLETO II RCT has just been published in JACC Int, November 2020.
For the first time, a DCB (Elutax SV/Emperor) outperformed a new-gen DES in terms of angiographic endpoint, in the native vessel disease setting.
I am including here the PDF version of the paper for your reference.j.jcin.2020.08.035